Compile Data Set for Download or QSAR
Report error Found 820 Enz. Inhib. hit(s) with Target = 'Proto-oncogene tyrosine-protein kinase receptor Ret [V804L]'
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 716172BDBM716172(US12209085, Example 215)
Affinity DataIC50: 0.0600nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 716174BDBM716174(US12209085, Example 214)
Affinity DataIC50: 0.100nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 716171BDBM716171(US12209085, Example 4)
Affinity DataIC50: 0.200nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 716173BDBM716173(US12209085, Example 194)
Affinity DataIC50: 0.230nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 311651BDBM311651(Ex. Cpd. 103 | US10807986, Example 103 | US1104669...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 311705BDBM311705(Ex. Cpd. 157 | US10807986, Example 157 | US1104669...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 716170BDBM716170(US12209085, Example 3)
Affinity DataIC50: 0.300nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 311700BDBM311700(Ex. Cpd. 152 | US10807986, Example 152 | US1104669...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 311643BDBM311643(Ex. Cpd. 95 | US10807986, Example 95 | US11046696,...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 311699BDBM311699(Ex. Cpd. 151 | US10807986, Example 151 | US1104669...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 311643BDBM311643(Ex. Cpd. 95 | US10807986, Example 95 | US11046696,...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 311699BDBM311699(Ex. Cpd. 151 | US10807986, Example 151 | US1104669...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 311717BDBM311717(Ex. Cpd. 169 | US10807986, Example 169 | US1104669...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 311700BDBM311700(Ex. Cpd. 152 | US10807986, Example 152 | US1104669...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 311717BDBM311717(Ex. Cpd. 169 | US10807986, Example 169 | US1104669...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 311622BDBM311622(Ex. Cpd. 59 | US10807986, Example 59 | US11046696,...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 311639BDBM311639(Ex. Cpd. 91 | US10807986, Example 91 | US11046696,...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 311639BDBM311639(Ex. Cpd. 91 | US10807986, Example 91 | US11046696,...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 311622BDBM311622(Ex. Cpd. 59 | US10807986, Example 59 | US11046696,...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 311699BDBM311699(Ex. Cpd. 151 | US10807986, Example 151 | US1104669...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 311651BDBM311651(Ex. Cpd. 103 | US10807986, Example 103 | US1104669...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 311705BDBM311705(Ex. Cpd. 157 | US10807986, Example 157 | US1104669...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 311634BDBM311634(Ex. Cpd. 86 | US10807986, Example 86 | US11046696,...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 311634BDBM311634(Ex. Cpd. 86 | US10807986, Example 86 | US11046696,...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 311723BDBM311723(Ex. Cpd. 175 | US10807986, Example 175 | US1104669...)
Affinity DataIC50: 0.400nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 311723BDBM311723(Ex. Cpd. 175 | US10807986, Example 175 | US1104669...)
Affinity DataIC50: 0.400nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 311652BDBM311652(Ex. Cpd. 104 | US10807986, Example 104 | US1104669...)
Affinity DataIC50: 0.400nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 311636BDBM311636(Ex. Cpd. 88 | US10807986, Example 88 | US11046696,...)
Affinity DataIC50: 0.400nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 311653BDBM311653(Ex. Cpd. 105 | US10807986, Example 105 | US1104669...)
Affinity DataIC50: 0.400nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 311653BDBM311653(Ex. Cpd. 105 | US10807986, Example 105 | US1104669...)
Affinity DataIC50: 0.400nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 311636BDBM311636(Ex. Cpd. 88 | US10807986, Example 88 | US11046696,...)
Affinity DataIC50: 0.400nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 311652BDBM311652(Ex. Cpd. 104 | US10807986, Example 104 | US1104669...)
Affinity DataIC50: 0.400nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 311660BDBM311660(Ex. Cpd. 112 | US10807986, Example 112)
Affinity DataIC50: 0.5nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 311703BDBM311703(Ex. Cpd. 155 | US10807986, Example 155 | US1104669...)
Affinity DataIC50: 0.5nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 311704BDBM311704(Ex. Cpd. 156 | US10807986, Example 156 | US1104669...)
Affinity DataIC50: 0.5nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 311704BDBM311704(Ex. Cpd. 156 | US10807986, Example 156 | US1104669...)
Affinity DataIC50: 0.5nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 311703BDBM311703(Ex. Cpd. 155 | US10807986, Example 155 | US1104669...)
Affinity DataIC50: 0.5nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 311660BDBM311660(Ex. Cpd. 112 | US10807986, Example 112)
Affinity DataIC50: 0.5nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 311679BDBM311679(Ex. Cpd. 131 | US10807986, Example 131 | US1104669...)
Affinity DataIC50: 0.5nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 311679BDBM311679(Ex. Cpd. 131 | US10807986, Example 131 | US1104669...)
Affinity DataIC50: 0.5nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 311707BDBM311707(Ex. Cpd. 159 | US10807986, Example 159 | US1104669...)
Affinity DataIC50: 0.5nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 311707BDBM311707(Ex. Cpd. 159 | US10807986, Example 159 | US1104669...)
Affinity DataIC50: 0.5nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 311637BDBM311637(Ex. Cpd. 89)
Affinity DataIC50: 0.600nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 311673BDBM311673(Ex. Cpd. 125 | US10807986, Example 125 | US1104669...)
Affinity DataIC50: 0.600nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 311691BDBM311691(Ex. Cpd. 143 | US10807986, Example 143 | US1104669...)
Affinity DataIC50: 0.600nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 469423BDBM469423(US10807986, Example 89 | US11046696, Compound 89)
Affinity DataIC50: 0.600nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 311673BDBM311673(Ex. Cpd. 125 | US10807986, Example 125 | US1104669...)
Affinity DataIC50: 0.600nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 311691BDBM311691(Ex. Cpd. 143 | US10807986, Example 143 | US1104669...)
Affinity DataIC50: 0.600nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 311700BDBM311700(Ex. Cpd. 152 | US10807986, Example 152 | US1104669...)
Affinity DataIC50: 0.600nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 311741BDBM311741(Ex. Cpd. 193 | US10807986, Example 193 | US1104669...)
Affinity DataIC50: 0.600nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

Displayed 1 to 50 (of 820 total ) | Next | Last >>
Jump to: